Last updated: August 5, 2026
Azilsartan medoxomil is a mature angiotensin II receptor blocker marketed primarily as Edarbi in the United States and Azilva in Japan. Its commercial trajectory is constrained by a crowded generic antihypertensive market, limited clinical differentiation versus established ARBs, and the absence of separately reported product revenue from Takeda. The principal commercial risk is generic substitution after regulatory and patent barriers expire, while the main growth opportunity is continued use in patients requiring an ARB with strong blood-pressure reduction and once-daily dosing.
What is the FDA status of azilsartan medoxomil?
Azilsartan medoxomil is an orally administered prodrug converted to azilsartan, a selective angiotensin II type 1 receptor antagonist. The FDA approved Edarbi tablets in February 2011 for hypertension in adults. Approved strengths are 20 mg, 40 mg, and 80 mg once daily [1].
The FDA label identifies Edarbi as a treatment for hypertension, either as monotherapy or in combination with other antihypertensive agents. The product is not approved to reduce cardiovascular mortality or major cardiovascular events independently of blood-pressure control [1].
Azilsartan medoxomil is also marketed with chlorthalidone as Edarbyclor. The fixed-dose combination was approved in 2012 and targets patients requiring an ARB plus a thiazide-like diuretic [2].
FDA regulatory profile
| Attribute |
Azilsartan medoxomil |
| Originator |
Takeda Pharmaceuticals |
| U.S. brand |
Edarbi |
| Combination brand |
Edarbyclor |
| Drug class |
Angiotensin II receptor blocker |
| FDA approval |
2011 |
| Dosage form |
Oral tablet |
| Strengths |
20 mg, 40 mg, 80 mg |
| Primary indication |
Hypertension |
| Biologic status |
Small molecule |
| Biosimilar pathway |
Not applicable |
| Reference NDA |
NDA 200796 |
| Pediatric exclusivity |
No material long-term exclusivity impact publicly associated with the product |
The product is regulated through the abbreviated new drug application pathway for generic competition. Generic manufacturers do not need to repeat the full clinical development program if they demonstrate pharmaceutical equivalence and bioequivalence.
When does azilsartan medoxomil lose exclusivity?
Azilsartan medoxomil has already lost new chemical entity exclusivity. The five-year NCE period attached to the 2011 approval expired in 2016, subject to the timing of any eligible patent certifications and regulatory activity [1, 3].
The commercial exclusivity analysis now depends primarily on:
- Orange Book-listed patents for Edarbi and Edarbyclor.
- Patent term adjustment or patent term extension.
- Paragraph IV certifications filed by generic applicants.
- Any litigation settlements or licenses.
- FDA approval timing for ANDAs.
The relevant patent issue is not a single universal expiration date for “azilsartan.” Patents can cover the active compound, crystalline or solid-state forms, formulations, combinations, or manufacturing processes. A generic applicant can challenge one or more listed patents while leaving other patents unchallenged.
What patents protect Edarbi?
The FDA Orange Book is the controlling public source for patents listed against the reference product. Listed patents may include compound and formulation protection, with expiration dates determined by the individual patent record and any approved term adjustment [3].
The core patent estate has historically included Takeda patents directed to azilsartan and related pharmaceutical compositions. The most commercially relevant protection has been the compound patent family and later formulation or solid-state patents. The strength of the estate has declined as the earliest protection approaches expiration and as generic companies gain the ability to challenge listed claims through ANDA litigation.
A patent-by-patent commercial conclusion requires the current Orange Book record, patent term calculations, and the status of any active district-court or Federal Circuit proceedings. Publicly available company filings do not provide a separate, comprehensive financial valuation for the Edarbi patent estate.
How many patents cover azilsartan medoxomil?
The number of potentially relevant patents depends on the product definition.
For Edarbi tablets, the relevant set can include:
- Compound patents covering azilsartan or azilsartan medoxomil.
- Composition-of-matter patents covering salts, prodrugs, or related chemical forms.
- Solid-state or polymorph patents.
- Tablet formulation patents.
- Manufacturing-process patents.
- Method-of-use patents for hypertension treatment.
- Combination-product patents covering Edarbyclor.
Not every patent in a broader azilsartan family is necessarily listed in the Orange Book. Process patents usually create a weaker immediate barrier to ANDA approval than a patent covering the active ingredient or finished dosage form. Method-of-use patents can be carved out through a section viii statement if the generic label omits the protected indication.
What formulation patents protect Edarbi and Edarbyclor?
Formulation protection matters because azilsartan medoxomil is a low-dose oral drug whose commercial product depends on consistent tablet manufacture, dissolution, and stability.
Potential formulation barriers include claims directed to:
- Tablet composition.
- Excipients and disintegrants.
- Dissolution performance.
- Solid-state form.
- Stability under storage conditions.
- Fixed-dose combinations with chlorthalidone.
Edarbyclor has a distinct patent analysis because the product contains two active ingredients and may have separate listed patents from Edarbi. A generic company seeking approval for azilsartan alone does not necessarily address all patents relevant to the combination product.
The commercial value of formulation patents is greatest when they cover a necessary product characteristic that is difficult to design around. Their value is lower when an ANDA applicant can use a different excipient system or demonstrate bioequivalence with a non-infringing formulation.
What method-of-use patents cover azilsartan medoxomil?
The principal approved use is treatment of hypertension. Method-of-use patents may cover dosing regimens, patient populations, combination therapy, or specific clinical contexts.
Their practical value is limited by the generic labeling process. A generic applicant may omit a patented indication or dosing instruction through a section viii statement. That approach can reduce infringement exposure if the remaining label does not actively encourage the patented use.
The hypertension market is broad, which makes complete exclusion of the indication commercially difficult. A carve-out label can still permit substantial substitution when physicians prescribe the generic for unprotected uses.
Which companies are challenging azilsartan medoxomil patents?
Generic competition can come from major manufacturers and India-based suppliers with U.S. ANDA capabilities, including companies such as Teva, Viatris, Sandoz, Zydus, Alembic, and Lupin. The public record should distinguish between:
- A company filing an ANDA.
- A company submitting a Paragraph IV certification.
- A company named in patent litigation.
- A company receiving tentative FDA approval.
- A company receiving final approval and launching.
These events are not equivalent. An ANDA filing does not establish that a product will reach the market. A Paragraph IV notice can trigger litigation and a 30-month stay, while a final approval can remain blocked by another listed patent or settlement restriction [3, 4].
No reliable public source supports assigning a current market share or launch date to each potential azilsartan generic without a live FDA approval and litigation review.
What is the Orange Book status of Edarbi?
Edarbi is listed in the FDA Orange Book as an approved prescription drug product. The Orange Book identifies the reference listed drug, dosage strengths, therapeutic equivalence information, and patents or exclusivity associated with the product when applicable [3].
The Orange Book does not provide a complete commercial forecast. It does not show:
- Actual generic launch probability.
- Settlement terms.
- Net pricing.
- Rebate levels.
- Pharmacy substitution rates.
- Manufacturer inventory.
- Market share by channel.
The relevant business conclusion is that Orange Book-listed protection remains important for launch timing, but it is only one part of the generic-entry analysis.
What patent litigation affects azilsartan medoxomil?
Patent litigation risk is concentrated around ANDA filings and Paragraph IV certifications. A patent suit can delay approval through the statutory 30-month stay, although the stay can be shortened or terminated by court action or settlement [4].
The most important litigation questions are:
- Whether the challenged patent covers the active ingredient or only a secondary feature.
- Whether the generic applicant’s formulation infringes.
- Whether the patent claims survive invalidity challenges.
- Whether the court grants a preliminary injunction.
- Whether the originator settles for a licensed entry date.
- Whether multiple generic applicants receive different launch rights.
A settlement can preserve a period of branded pricing while granting one or more generic manufacturers an agreed launch date. The financial effect depends on whether the settlement creates a first-filer advantage, permits authorized generic competition, or allows several suppliers to enter simultaneously.
A definitive current litigation conclusion requires the active docket and the latest Orange Book record. Takeda’s public financial filings do not disclose a product-level litigation reserve or expected loss attributable specifically to azilsartan medoxomil [5].
How does azilsartan compare with competing ARBs?
Azilsartan competes with losartan, valsartan, irbesartan, candesartan, olmesartan, and telmisartan. Most competing ARBs are available generically and have established formulary positions.
| Product |
Active ingredient |
Market position |
Generic pressure |
Differentiation |
| Edarbi |
Azilsartan medoxomil |
Branded ARB |
High |
Once-daily dosing and strong BP reduction |
| Diovan |
Valsartan |
Mature ARB |
Very high |
Broad historical use and cardiovascular indications |
| Benicar |
Olmesartan |
Mature ARB |
Very high |
Established hypertension franchise |
| Atacand |
Candesartan |
Mature ARB |
Very high |
Heart-failure and hypertension use |
| Micardis |
Telmisartan |
Mature ARB |
Very high |
Long half-life and additional risk-reduction positioning |
| Cozaar |
Losartan |
First-in-class ARB |
Very high |
Low-cost, broad availability |
| Edarbyclor |
Azilsartan/chlorthalidone |
Branded combination |
High |
ARB plus chlorthalidone in one tablet |
Azilsartan’s clinical differentiation is based mainly on blood-pressure reduction and pharmacologic profile. It does not have a clearly established outcome advantage that would allow it to command a durable premium over generic ARBs across the overall hypertension market [1, 6].
What are the main market dynamics for azilsartan medoxomil?
Generic substitution and price erosion
The principal market force is generic substitution. Hypertension treatment is a high-volume, price-sensitive category in which payers generally prefer low-cost generic ARBs. Once multiple generic suppliers enter, wholesale acquisition price and net price can decline sharply.
The first approved generic may retain a temporary price premium, particularly if it has limited competition. That premium usually contracts as additional manufacturers enter.
Formulary and payer pressure
Edarbi must compete with generic ARBs that are commonly placed on preferred formulary tiers. Prior authorization, step therapy, and higher patient cost sharing can restrict branded use.
The product is more likely to retain demand in patients who:
- Require a specific physician-selected ARB.
- Have inadequate blood-pressure control on another agent.
- Remain on an established branded regimen.
- Have access through commercial insurance or manufacturer assistance.
- Use the fixed-dose Edarbyclor combination.
Clinical positioning
Azilsartan can be positioned as a potent once-daily ARB, but hypertension treatment guidelines emphasize blood-pressure control, tolerability, adherence, and cost. Those factors favor generic alternatives when clinical outcomes are otherwise comparable [6].
Geographic variation
The United States is the most visible patent and ANDA market. Japan is important because Takeda commercialized azilsartan as Azilva and because Japan has a distinct reimbursement and generic-substitution system. Other countries may have local brands, licenses, or different patent outcomes.
Patent expiry and generic entry are jurisdiction-specific. A U.S. patent challenge does not determine market entry in Japan, Europe, China, or emerging markets.
What licensing deals affect azilsartan medoxomil?
Takeda developed azilsartan and commercialized it through the Edarbi and Azilva brands. Public Takeda filings report product and regional performance at portfolio or business-unit levels rather than providing a dependable annual revenue series for azilsartan medoxomil alone [5].
The absence of separately reported revenue limits the ability to quantify:
- Global Edarbi sales.
- U.S. versus Japan revenue.
- Net price after rebates.
- Royalty obligations.
- License payments.
- Product-level operating margin.
Public licensing information should be separated from ordinary distribution or commercialization arrangements. A regional commercial agreement does not necessarily transfer patent ownership or global development rights.
What is the financial trajectory of azilsartan medoxomil?
Azilsartan’s financial trajectory is consistent with a mature branded antihypertensive:
- Launch phase: Takeda established Edarbi in the U.S. after the 2011 FDA approval, supported by physician promotion and hypertension-market positioning.
- Expansion phase: Edarbyclor broadened the franchise into combination therapy after its 2012 approval.
- Maturity phase: The product faced generic ARB competition, formulary restrictions, and limited differentiation in a crowded class.
- Exclusivity transition: Patent and ANDA developments became more important than new clinical expansion.
- Post-generic phase: Revenue exposure is expected to shift from branded sales toward residual branded demand, authorized-generic economics, or licensing income if applicable.
Takeda’s financial reports do not isolate Edarbi revenue. As a result, revenue exposure cannot be responsibly calculated from company disclosures alone. The product is unlikely to be a major driver of Takeda’s consolidated financial performance relative to its oncology, gastroenterology, rare-disease, plasma-derived, and vaccine portfolios [5].
How strong is the azilsartan patent estate?
The patent estate is moderate to weak from a long-term revenue-protection perspective.
Its strengths are:
- A recognized composition-of-matter and product patent history.
- Multiple possible claim categories, including formulation and combination protection.
- Regulatory delay mechanisms linked to ANDA litigation.
- A branded combination product with a separate patent analysis.
Its weaknesses are:
- Loss of NCE exclusivity.
- A crowded ARB market.
- Design-around potential for formulation claims.
- Limited value of method-of-use claims where label carve-outs are available.
- Strong payer incentives to substitute generic ARBs.
- No biologic manufacturing complexity.
The estate may delay or shape generic entry, but it is unlikely to support long-duration premium pricing comparable with a protected specialty or biologic medicine.
What generic launch scenarios exist for Edarbi?
| Scenario |
Market effect |
| No approved generic before final patent expiry |
Brand retains pricing longer, but pressure increases at expiry |
| One first-filer generic |
Moderate initial erosion and possible limited competition |
| Several simultaneous generic launches |
Rapid price compression and high substitution |
| Settlement with licensed entry |
Predictable erosion beginning on the agreed date |
| Formulation patent survives but compound patent expires |
Generic entry may occur through a non-infringing formulation |
| Patent invalidation or dismissal |
Earlier-than-expected generic entry |
| Edarbyclor-specific delay |
Edarbi and Edarbyclor can experience different erosion timing |
For investors and licensors, the key variable is not only the first legal entry date. It is the number of suppliers entering during the first six to 12 months, the existence of an authorized generic, and the share of prescriptions controlled by restricted formularies.
Key Takeaways
- Azilsartan medoxomil is a mature small-molecule ARB marketed as Edarbi in the United States and Azilva in Japan.
- The FDA approved Edarbi in 2011 and Edarbyclor in 2012.
- NCE exclusivity has expired; future protection depends on listed patents, litigation, settlements, and ANDA timing.
- Generic substitution is the central commercial risk.
- The product competes against low-cost generic losartan, valsartan, olmesartan, candesartan, irbesartan, and telmisartan.
- Takeda does not separately report reliable product-level azilsartan revenue in its public financial statements.
- Azilsartan has no biosimilar risk because it is a chemically synthesized small molecule.
- Formulation and combination patents may affect timing, but they are less durable than broad composition-of-matter protection.
- The financial outlook is mature to declining unless branded persistence, regional licensing, or delayed generic entry supports residual revenue.
FAQs
Is azilsartan medoxomil still commercially significant?
It remains commercially relevant as a branded hypertension product and as a potential generic product, but it is not a major disclosed revenue driver for Takeda.
Is Edarbi more effective than losartan?
Clinical studies show strong blood-pressure reduction with azilsartan, but no broad outcome-based superiority has established Edarbi as a replacement for inexpensive generic ARBs across the hypertension market [1, 6].
Does azilsartan medoxomil have biosimilar competition?
No. Azilsartan medoxomil is a small-molecule drug. Competition occurs through ANDAs and generic tablets, not biosimilar applications.
Is Edarbyclor protected by the same patents as Edarbi?
Not necessarily. Edarbyclor contains azilsartan medoxomil and chlorthalidone and can have separate formulation, combination, or method-of-use patents.
What would cause the fastest decline in Edarbi revenue?
The fastest decline would likely follow approval of several therapeutically equivalent generics, unrestricted pharmacy substitution, favorable formulary placement for generics, and the absence of an effective settlement or surviving patent barrier.
References
-
U.S. Food and Drug Administration. (2023). Edarbi (azilsartan medoxomil) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2023). Edarbyclor (azilsartan medoxomil and chlorthalidone) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
-
Takeda Pharmaceutical Company Limited. (2024). Annual report and integrated report. Takeda.
-
Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115.
